Free Trial
NASDAQ:CDT

Conduit Pharmaceuticals (CDT) Stock Price, News & Analysis

Conduit Pharmaceuticals logo
$0.10 0.00 (0.00%)
(As of 11/22/2024 ET)

About Conduit Pharmaceuticals Stock (NASDAQ:CDT)

Key Stats

Today's Range
$0.10
$0.11
50-Day Range
$0.09
$0.14
52-Week Range
$0.08
$7.83
Volume
24.85 million shs
Average Volume
36.03 million shs
Market Capitalization
$10.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Receive CDT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conduit Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CDT Stock News Headlines

Conduit Pharmaceuticals receives further patent approval for AZD1656
What's Going On With Conduit Pharmaceuticals Shares Today?
Let’s be blunt
Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!
Conduit Pharmaceuticals Announces Leadership Changes and Bylaws Update
Conduit Pharmaceuticals announces new addition to autoimmune pipeline
See More Headlines

CDT Stock Analysis - Frequently Asked Questions

Conduit Pharmaceuticals' stock was trading at $4.55 at the beginning of 2024. Since then, CDT stock has decreased by 97.7% and is now trading at $0.1040.
View the best growth stocks for 2024 here
.

Shares of CDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Conduit Pharmaceuticals investors own include BIOLASE (BIOL), Daré Bioscience (DARE), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Cara Therapeutics (CARA), Canoo (GOEV) and Jiuzi (JZXN).

Company Calendar

Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CDT
Previous Symbol
NASDAQ:CDT
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Net Income
$-540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.09) per share

Miscellaneous

Free Float
67,119,000
Market Cap
$10.70 million
Optionable
Not Optionable
Beta
2.14
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NASDAQ:CDT) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners